Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8258898 | 0.85 | TSHR (0.47) | TSHRSMN1; SMN2GLAHDAC3HDAC4 | |
| SCHEMBL4942582 | 0.84 | TSHR (0.58) | TSHRSMN1; SMN2GLAEPHX2ALDH1A1 | |
| SCHEMBL14086615 | 0.82 | TSHR (0.44) | TSHRSMN1; SMN2GLAHDAC3HDAC4 | |
| SCHEMBL14086619 | 0.82 | TSHR (0.44) | TSHRSMN1; SMN2GLAHDAC3HDAC4 | |
| SCHEMBL8885696 | 0.80 | TSHR (0.54) | TSHRSMN1; SMN2EPHX2EPHX1ALDH1A1 | |
| SCHEMBL14086618 | 0.80 | HDAC3 (0.46) | TSHRSMN1; SMN2GLAHDAC3HDAC4 | |
| SCHEMBL14086622 | 0.80 | TP53 (0.51) | TSHRSMN1; SMN2HDAC3HDAC4HDAC1 | |
| SCHEMBL29294424 | 0.80 | SMN1; SMN2 (0.49) | TSHRSMN1; SMN2GLAEPHX2ALDH1A1 | |
| SCHEMBL863016 | 0.79 | ITGB3 (0.50) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL560936 | 0.79 | EPHX2 (0.53) | TSHRSMN1; SMN2EPHX2EPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143256-B2 | 5-(4-{4-[A7-(3,5-diamino-6-chloropyrazine-2 carbonyl)guanadio]butyl}-piperazin-1-yl)pentanoic acid (3-dimethylaminopropyl) amide; hydration of mucosal surfaces; Chronic bronchitis; cystic fibrosis; more potent; absorbed slower; target kidney in treating cardiovascular disease; diuretics | PARION SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080096896-A1 | Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers | PARION SCIENCES, INC. (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096896-A1 | Cyclic Amide & Ester Pyrazinoylganidine Sodium Channel Blockers | HCN4, CACNA1B, SCN5A | TSHR 2553/4885SMN1; SMN2 2531/4885GLA 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.